11β-hydroxylase deficiency screening: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{11β-hydroxylase deficiency}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{MJ}} | ||
==Overview== | ==Overview== | ||
There is insufficient evidence to recommend routine screening for 11β-hydroxylase deficiency. | |||
==Screening== | ==Screening== | ||
There is insufficient evidence to recommend routine screening for 11β-hydroxylase deficiency. | |||
==References== | ==References== | ||
Latest revision as of 14:37, 3 August 2017
|
11β-hydroxylase deficiency Microchapters |
|
Differentiating 11β-hydroxylase deficiency from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
11β-hydroxylase deficiency screening On the Web |
|
American Roentgen Ray Society Images of 11β-hydroxylase deficiency screening |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency |
|
Risk calculators and risk factors for 11β-hydroxylase deficiency screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Overview
There is insufficient evidence to recommend routine screening for 11β-hydroxylase deficiency.
Screening
There is insufficient evidence to recommend routine screening for 11β-hydroxylase deficiency.